Pharming Group (OTCMKTS:PHGUF) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.
A number of other equities analysts have also recently weighed in on PHGUF. Zacks Investment Research cut Pharming Group from a “hold” rating to a “sell” rating in a research note on Wednesday, August 23rd. HC Wainwright reissued a “buy” rating on shares of Pharming Group in a research note on Thursday, October 26th.
Pharming Group (PHGUF) opened at $1.45 on Friday. Pharming Group has a 12 month low of $0.25 and a 12 month high of $1.58. The company has a quick ratio of 1.27, a current ratio of 1.77 and a debt-to-equity ratio of 11.72.
ILLEGAL ACTIVITY WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/03/pharming-group-phguf-stock-rating-lowered-by-valuengine.html.
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
What are top analysts saying about Pharming Group NV? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pharming Group NV and related companies.